drug · protein
leuprolide mesylate
Marketedupdated 3mo agoby Foresee Pharmaceuticals Co Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for prostate cancer and 1 investigational indication.
indications
investigational
Prostate Cancer
targets
Gonadotropin-releasing hormone receptor
all catalysts(0)
nothing on the calendar yet
Trials studying leuprolide mesylate
- phase3Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
- phase3The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 16, 2027
158 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- Jan 1, 2039formulationUS 11717555
- Dec 18, 2037formulationUS 12133878
- Jan 16, 2027formulationUS 10646572158d
- Jan 16, 2027formulationUS 9572857158d
- Jan 16, 2027formulationUS 9744207158d
FDA exclusivities (1)
- Aug 25, 2028NSNS2.0y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that